.Dana-Farber's Vinayak Venkataraman, MD spoke with CURE Today about how emerging second- and third-line therapeutic strategies and investigational agents may shift the standard of care for patients with GIST. ➡️ bit.ly/3LI7yry

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors #GIST ⁦The Life Raft Group⁩ ⁦Sarcoma Foundation of America⁩ ⁦Sarcoma UK⁩ ⁦SPAGN⁩ ⁦PAWSGIST⁩ ⁦Sylvester Comprehensive Cancer Center⁩ finance.yahoo.com/news/cogent-bi…

Heading to #CTOS25? Check out this list of Dana-Farber research presentations, panels, and posters that will be presented at the conference in Boca Raton, FL from Nov. 12-15.

Surreal to be at CTOS without the irreplaceable BVT. There was no better advocate for sarcoma patients, sarcoma science, and sarcoma focused junior faculty . #CTOS2025

#ARTEMIS-002: #HS20093 is a B7:H3 #ADC demonstrated promising efficacy in #phase 2 #multiple cohorts of #osteosarcomas and #othersarcomas. Dose dependent relationship: 12mg/kg Q3w led to PFS 8.4months, PFSR6 66.6% in previously pre-treated osteosarcoma patients.

Micvotabart pelidotin with some encouraging activity in hard to treat sarcomas. Strong Boston representation on the podium.💪🏻☘️ #CTOS2025

Mentor ⁦Vinod Ravi, MD⁩ presenting very interesting data of TGFb trap and checkpoint inhibitor to for angiosarcoma. Good activity in heavily pretreated patients #CTOS2025

Mentee Gal Strauss Dana-Farber presenting our descriptive analysis of the #angiosarcoma microenvironment. Can we better define who responds to ICI?

So exciting to see clear evidence of activity in #chondrosarcoma #CTOS2025 🦴

Tumor reduction with a TEAD inhibitor for #EHE. Exciting early data from #sarcoma Dana-Farber superstar Dr Candace Haddox #CTOS2025

This is the most forward looking approach the FDA has taken with the expansion of scientific knowledge today. Well done Vinay Prasad MD MPH Dr. Marty Makary. I love these statements: "An appropriately designed study with a small sample size can support licensure of a product for which

Super cool large language model AI work looking at #sarcoma clinical data. #CTOS2025

🐦 joined for the annual sarculator talk #CTOS2025

RT associated #angiosarcoma of the breast/chest wall “debate”. “See five experts get six different opinions”. Management guided by strong belief and little data. To be continued at the next meetings…. #CTOS2025

What makes dedifferentiated liposarcoma dedifferentiated? Important insights from new ⁦Dana-Farber⁩ sarcoma faculty Dr. Erica Pimenta. Another area for GLP1 research? #CTOS2025

Differential would also include angiosarcoma especially if had been treated with radiation therapy

Back home from #CTOS2025, but I want to remind people that the Sarcoma Alliance will reimburse expenses up to $1,000 for patients who travel to get a second opinion from a sarcoma specialist. sarcomaalliance.org/second-opinion…

I often hear "I wish we didn't have to waste these $$$ meds every time a patient stops & has extra left over." Here's what the state of Michigan did to combat this: - Statewide cancer drug repository, 105 sites - $26M value/>100K pills donated to >1K pts ascopubs.org/doi/10.1200/OP…